Polyethylene glycol conjugation at Cys232 prolongs the half-life of α1 Proteinase inhibitor

American Journal of Respiratory Cell and Molecular Biology

Volumn 27, Issue 6, 2002, Pages 659-665

  Cantin, André M ^a,b   Woods, Donald E ^a,b   Cloutier, Diane ^a,b   Dufour, Erick K ^a,b   Leduc, Richard ^a,b  

^a UNIVERSITY OF SHERBROOKE   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALIA;

EID: 0036891151     PISSN: 10441549     EISSN: None     Source Type: Journal    
DOI: 10.1165/rcmb.4866     Document Type: Article

References (36)

1. Lee, W. L., and G. P. Downey. 2001. Leukocyte elastase: Physiological functions and role in acute lung injury. Am. J. Respir. Crit. Care Med. 164:896-904.
2. Wewers, M. 1989. Pathogenesis of emphysema: Assessment of basic science concepts through clinical investigation. Chest 95:190-195.
3. Jackson, A. H., S. L. Hill, S. C. Afford, and R. A. Stockley. 1984. Sputum sol-phase proteins and elastase activity in patients with cystic fibrosis. Eur. J. Respir. Dis. 65:114-124.
4. Cowan, K. N., A. Heilbut, T. Humpl, C. Lam, S. Ito, and M. Rabinovitch. 2000. Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor. Nat. Med. 6:698-702.
5. Obayashi, Y., I. Yamadori, J. Fujita, T. Yoshinouchi, N. Ueda, and J. Takahara. 1997. The role of neutrophils in the pathogenesis of idiopathic pulmonary fibrosis. Chest 112:1338-1343.
6. Seersholm, N., M. Wencker, N. Banik, K. Viskum, A. Dirksen, A. Kok-Jensen, and N. Konietzko. 1997. Does α1-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary α1-antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) α1-AT study group. Eur. Respir. J. 10:2260-2263.
7. Birrer, P. 1995. Proteases and antiproteases in cystic fibrosis: Pathogenetic considerations and therapeutic strategies. Respiration 62:25-28.
8. McElvaney, N. G., R. C. Hubbard, P. Birrer, M. S. Chernick, D. B. Caplan, M. M. Frank, and R. G. Crystal. 1991. Aerosol α1-antitrypsin treatment for cystic fibrosis. Lancet 337:392-394.
9. Cantin, A. M., and D. E. Woods. 1999. Aerosolized prolastin suppresses bacterial proliferation in a model of chronic Pseudomonas aeruginosa lung infection. Am. J. Respir. Crit. Care Med. 160:1130-1135.
10. Berger, M., R. U. Sorensen, M. F. Tosi, D. G. Dearborn, and G. Doring. 1989. Complement receptor expression on neutrophils at an inflammatory site, the Pseudomonas-infected lung in cystic fibrosis. J. Clin. Invest. 84:1302-1313.
11. Tosi, M. F., H. Zakem, and M. Berger. 1990. Neutrophil elastase cleaves C3bi on opsonized pseudomonas as well as CR1 on neutrophils to create a functionally important opsonin receptor mismatch. J. Clin. Invest. 86:300-308.
12. Tebbutt, S. J. 2000. Technology evaluation: Transgenic alpha-1-antitrypsin (AAT), PPL therapeutics. Curr. Opin. Mol. Ther. 2:199-204.
13. Monfardini, C., and F. M. Veronese. 1998. Stabilization of substances in circulation. Bioconjug. Chem. 9:418-450.
14. Chapman, A. P., P. Antoniw, M. Spitali, S. West, S. Stephens, and D. J. King. 1999. Therapeutic antibody fragments with prolonged in vivo half-lives. Nat. Biotechnol. 17:780-783.
15. Silverman, G. A., P. I. Bird, R. W. Carrell, F. C. Church, P. B. Coughlin, P. G. Gettins, J. A. Irving, D. A. Lomas, C. J. Luke, R. W. Moyer, P. A. Pemberton, E. Remold-O'Donnell, G. S. Salvesen, J. Travis, and J. C. Whisstock. 2001. The serpins are an expanding superfamily of structurally similar but functionally diverse proteins: Evolution, mechanism of inhibition, novel functions, and a revised nomenclature. J. Biol. Chem. 276:33293-33296.
16. Tyagi, S. C. 1991. Reversible inhibition of neutrophil elastase by thiol-modified alpha-1 protease inhibitor. J. Biol. Chem. 266:5279-5285.
17. Travis, J., J. Bowen, D. Tewksbury, D. Johnson, and R. Pannell. 1976. Isolation of albumin from whole human plasma and fractionation of albumin-depleted plasma. Biochem. J. 157:301-306.
18. Cantin, A., G. Bilodeau, and R. Begin. 1989. Granulocyte elastase-mediated proteolysis of alpha 1-antitrypsin in cystic fibrosis bronchopulmonary secretions. Pediatr. Pulmonol. 7:12-17.
19. Dufour, E. K., J. B. Denault, P. C. Hopkins, and R. Leduc. 1998. Serpin-like properties of alpha1-antitrypsin Portland towards furin convertase. FEBS Lett. 426:41-46.
20. Sugiura, M., S. Hayakawa, T. Adachi, Y. Ito, K. Hirano, and S. Sawaki. 1981. A simple one-step purification of human α1-proteinase inhibitor by immunoadsorbent column chromatography. J. Biochem. Biophys. Methods 5:243-249.
21. Bradford, M. M. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:248-254.
22. Jameson, G. W., D. V. Roberts, R. W. Adams, W. S. Kyle, and D. T. Elmore. 1973. Determination of the operational molarity of solutions of bovine alpha-chymotrypsin, trypsin, thrombin and factor Xa by spectrofluorimetric titration. Biochem. J. 131:107-117.
23. Ogushi, F., G. A. Fells, R. C. Hubbard, S. D. Straus, and R. G. Crystal. 1987. Z-type alpha 1-antitrypsin is less competent than M1-type alpha 1-antitrypsin as an inhibitor of neutrophil elastase. J. Clin. Invest. 80:1366-1374.
24. Cantin, A. M., S. Lafrenaye, and R. O. Begin. 1991. Antineutrophil elastase activity in cystic fibrosis serum. Pediatr. Pulmonol. 11:249-253.
25. Hunter, W. M., and R. C. Greenwood. 1962. Preparation of iodine-131 labelled human growth hormone of high specific radioactivity. Nature 194:495-496.
26. Cantin, A. M. 1998. DNase I acutely increases cystic fibrosis sputum elastase activity and its potential to induce lung hemorrhage in mice. Am. J. Respir. Crit. Care Med. 157:464-469.
27. Laemmli, U. K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685.
28. Vogelmeier, C., I. Kirlath, S. Warrington, N. Banik, E. Ulbrich, and R. M. Du Bois. 1997. The intrapulmonary half-life and safety of aerosolized alpha1-protease inhibitor in normal volunteers. Am. J. Respir. Crit. Care Med. 155:536-541.
29. Casolaro, M. A., G. Fells, M. Wewers, J. E. Pierce, F. Ogushi, R. Hubbard, S. Sellers, J. Forstrom, D. Lyons, G. Kawasaki, and R. G. Crystal. 1987. Augmentation of lung antineutrophil elastase capacity with recombinant human α-1-antitrypsin. J. Appl. Physiol. 63:2015-2023.
30. Kurfurst, M. M. 1992. Detection and molecular weight determination of polyethylene glycol-modified hirudin by staining after sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Anal. Biochem. 200:244-248.
31. Mast, A. E., G. Salvesen, H. P. Schnebli, and S. V. Pizzo. 1990. Evaluation of the rapid plasma elimination of recombinant alpha 1-proteinase inhibitor: Synthesis of polyethylene glycol conjugates with improved therapeutic potential. J. Lab. Clin. Med. 116:58-65.
32. Mast, A. E., G. Salvesen, F. H. Brucato, H. P. Schnebli, and S. V. Pizzo. 1990. Polyethylene glycol modification of serpins improves therapeutic potential. Biol. Chem. Hoppe Seyler 371:101-109.
33. Beauchamp, C. O., S. L. Gonias, D. P. Menapace, and S. V. Pizzo. 1983. A new procedure for the synthesis of polyethylene glycol-protein adducts; effects on function, receptor recognition, and clearance of superoxide dismutase, lactoferrin, and alpha 2-macroglobulin. Anal. Biochem. 131:25-33.
34. Hubbard, R. C., M. A. Casolaro, M. Mitchell, S. E. Sellers, F. Arabia, M. A. Matthay, and R. G. Crystal. 1989. Fate of aerosolized recombinant DNA-produced alpha 1-antitrypsin: Use of the epithelial surface of the lower respiratory tract to administer proteins of therapeutic importance. Proc. Natl. Acad. Sci. USA 86:680-684.
35. Monfardini, C., O. Schiavon, P. Caliceti, M. Morpurgo, J. M. Harris, and F. M. Veronese. 1995. A branched monomethoxypoly(ethylene glycol) for protein modification. Bioconjug. Chem. 6:62-69.
36. Elliott, P. R., X. Y. Pei, T. R. Dafforn, and D. A. Lomas. 2000. Topography of a 2.0 A structure of alpha1-antitrypsin reveals targets for rational drug design to prevent conformational disease. Protein Sci. 9:1274-1281.